Editor's note

This ExpertREACT article was originally published on 11 March 2011. Financial results and market positions described reflect the state of knowledge at that date.

$22bn in 2010: nearly quadruple 2003 levels

According to VacZine Analytics' calculations, the top five vaccine players sold approximately $22bn in vaccines in 2010, compared with nearly $19bn in 2009 - an impressive year-on-year increase of approximately 18%. Looking back to 2003 (approximately $6bn), the top five players had nearly quadrupled their business in seven years, achieving a CAGR of approximately 19%. One of the most surprising observations was the continued strong contribution of pandemic influenza vaccine revenues into 2010: an estimated $3.7bn from the top five players - an increase of approximately $700m over 2009 - largely as Q1 carry-over from prior-year government orders.

In the seasonal influenza segment, 2010 was a strong year for Sanofi Pasteur, which reported record seasonal vaccine results at €845m (FY 2010), a 33% increase at constant exchange rates. A 54.4% increase in US sales - where the company claimed greater than 50% market share - was attributed to widened ACIP recommendations and a post-H1N1 "awakening" of the general public to the importance of influenza vaccination. Sanofi sold 320 million doses of influenza vaccines (pandemic and seasonal) in 2010. GSK Biologicals sold the most in dollar terms with $6.7bn in revenues, with its emerging markets and "Rest of World" regions each now exceeding $1.4bn - surpassing US revenues.

Top 5 vaccine sales FY 2010
~$22bn
CAGR of approximately 19% since 2003; an 18% increase on 2009 in non-comparable terms

Meningitis as the near-term growth catalyst

VacZine Analytics identified significant near-term upside in meningococcal vaccines, particularly as Novartis Vaccines advanced MenB towards regulatory filing. The key message for investors and industry observers was that pandemic revenues, while an unexpected windfall, had obscured the genuine underlying growth momentum of the vaccine industry in emerging markets and new paediatric and adolescent recommendations. Companies were at pains to strip out H1N1 comparators to demonstrate double-digit underlying growth, with most forecasting continued expansion irrespective of pandemic vaccine contribution.